160 likes | 166 Views
Explore the decline in reported gonorrhea cases in NYC, analyzing rates by sex, age, and provider type from 1970 to 2005. Investigate factors contributing to the decrease, potential impacts on screening practices, and considerations for manufacturers of diagnostic tests.
E N D
Decline in reported GC morbidity in NYC Preeti Pathela ppathela@health.nyc.gov
Gonorrhea Where do we stand? NYC NYC NYC US US Cases per 100,000 pop. US
Gonorrhea Rates: United States, 1970-2004 and the Healthy People 2010 target -74% -12%
Gonorrhea Rates by Sex: United States, 1981-2004 and the Healthy People 2010 target
Gonorrhea Rates by Sex New York City, 1995-2005 Data based on cases reported to the NYC DOHMH
Gonorrhea Rates by Provider Type: United States, 1984-2004
Case rate (per 100,000 population) of Neisseria gonorrhea reported to the New York City DOHMH, with percent reported from Bureau of STD clinics, 2000-2005, by sex Data based on cases reported to the NYC DOHMH
Provider types in NYC BSTDC Surveillance Database HIV Counseling & Testing STD Clinic Drug Treatment Family Planning Prenatal Other Clinic Private Physician Hospital Correctional Facility Laboratory Other Unknown
N=6720 N=6330 N=5286 N=5507
NYC DOHMH Reported female gonorrhea cases, by provider type 2002 - 2005 N=6646 N=6691 N=5544 N=5048
Gonorrhea reported to the NYC DOHMH. Case rates (per 100,000 population) by age and sex*, full year 2004 Males Females N=5286 N=5544 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+ Age (years) Case rate /100,000 population * Excludes persons for whom age or sex information is missing.
What is leading to the apparent decline in GC cases? • A true decline in GC • Changes in screening practices • Use of diagnostic tests with different sensitivities • Changes in reporting practices
If decreases are true decreases… • How would this impact targeting of GC screening? • Could this impact manufacturers of tests (provision of Ct-only tests) for low GC prevalence areas?